Navigation Links
AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
Date:9/21/2009

ting GI problems, no clinically relevant drug-related adverse events or changes in laboratory safety parameters were observed.

"Prolonged courses of stable disease with minimal to no toxicity are encouraging signs", said Dr. Von Hoff. "The applications for an oral agent with these mechanisms of action are numerous."

Paul Blake, MD, AEterna Zentaris Senior Vice President and Chief Medical Officer added, "We are pleased with these Phase 1 results on AEZS-112, which indicate the potential for safe combination with other anticancer drugs. We now look forward to working on the further development of AEZS-112 in collaboration with our expert investigators."

About the AEZS-112 Phase 1 Study

This open-label, dose-escalation, multi-center, intermittent treatment Phase 1 study included patients with advanced solid tumors and lymphoma who had either failed standard therapy or for whom no standard therapy existed. Patients received a once-a-week oral administration of AEZS-112 for three consecutive weeks, followed by a one-week period without treatment. The cycles were repeated every four weeks based on tolerability and response, basically planned for up to four cycles, but allowing for continuation in case of potential benefit for the patient. The starting dose of AEZS-112 in this study was 13 mg/week, with doubling of doses in subsequent cohorts in the absence of significant toxicity. Primary endpoints of the Phase 1 trial focused on determining the safety and tolerability of AEZS-112 (maximum tolerated dose, MTD), as well as establishing a recommended Phase 2 dose and regimen. Secondary endpoints aimed at establishing the pharmacokinetics and determining the efficacy based on standard response criteria.

Preliminary results from this study were presented recently at the American Association for Cancer Research (AACR) Annual Meeting in Denver, Colorado. Poster #5567 entitled, "Phase I dose-escalation, safety, and pharma
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
2. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
3. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
5. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
6. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
7. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
9. AEterna Zentaris Receives US$10 Million from Institutional Investors
10. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
11. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... SAN BRUNO, Calif. , Nov. 18, 2014 ... is a platinum sponsor of the 10th Annual World Stem ... and regenerative medicine stakeholders. The 2014 World Stem Cell Summit ... San Antonio, Texas . ... the discovery and development of lifesaving cures and therapies, convening ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – ... a professor in the Regulatory Biology Laboratory at the Salk ... points to an “off switch” for drug resistance in cancer. ... local research is making a global impact in the fight ... join host Cheryl K. Goodman, CEO of Social Global Mobile ...
(Date:11/18/2014)... Texas (PRWEB) November 18, 2014 ... Polytetrahydrofuran (PTMEG) Industry is professional and in-depth ... gives Polytetrahydrofuran basic information, including its definition, ... also industry outline. This exploration covers the ... and worldwide industry examination covering macroeconomic environment ...
(Date:11/18/2014)... 2014  Great Basin Scientific, Inc. (NASDAQ: GBSN ... will host a conference call and webcast to provide an ... Nov. 20, at 4:30 pm EST time. "We ... Company,s recent IPO and would like to provide our investors ... Ryan Ashton , President and Chief Executive Officer of Great ...
Breaking Biology Technology:Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3Great Basin Scientific Announces Conference Call to Provide Update on Corporate Progress 2
... Ambulance Established in Monterrey, MONTERREY, Mexico, and ... Sangui BioTech GmbH,executives jointly opened another wound management ... occasion of a three day working visit. Sangui,BioTech ... Renate Pentzien discussed the next steps of the ...
... approach to a more effective sunscreen , Chronic ... developing skin cancer because UV light from the sun can ... grow in an uncontrolled manner. Hope for a new sunscreen ... been provided by a new study in a mouse model ...
... WALTHAM, Mass., Dec. 3 Thermo Fisher,Scientific Inc. (NYSE: ... today,announced that the China Doping Control Center (CDCC) has ... instrumentation and software for,the testing of athletes at the ... by the Chinese government and the International Olympic,Committee (IOC) ...
Cached Biology Technology:Sangui Partnership Enters a New Phase: 2Sangui Partnership Enters a New Phase: 3Sangui Partnership Enters a New Phase: 4JCI table of contents: Dec. 3, 2007 2JCI table of contents: Dec. 3, 2007 3JCI table of contents: Dec. 3, 2007 4JCI table of contents: Dec. 3, 2007 5JCI table of contents: Dec. 3, 2007 6JCI table of contents: Dec. 3, 2007 7JCI table of contents: Dec. 3, 2007 8JCI table of contents: Dec. 3, 2007 9JCI table of contents: Dec. 3, 2007 10JCI table of contents: Dec. 3, 2007 11JCI table of contents: Dec. 3, 2007 12JCI table of contents: Dec. 3, 2007 13Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing 2Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing 3Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing 4
(Date:11/6/2014)... TALLAHASSEE, Fla. -- A groundbreaking paper from a team ... better understanding of how plants could adapt to and ... The research, published in the latest issue of the ... how chromatin (the complex of DNA and proteins) is ... material, so that some genes are turned on and ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
(Date:11/5/2014)... Rio de Janeiro, Brazil -Individuals show great diversity in ... importantly, males and females greatly differ in their perceptual ... kinds of smell tests. , Sex differences ... social behaviors and may be connected to one,s perception ... and emotions. Thus, women,s olfactory superiority has been suggested ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2
... EUREKA Chairmanship 2009/2010! The conference, hosted and conceptually designed ... be held on July 6-7, 2009, at Maritim Hotel ... heart of the city, only a few steps away ... the current and future opportunities and challenges for Europe,s ...
... used by millions worldwide to effectively lower blood cholesterol ... Sclerosis (MS) patients treated with high daily dosages. ... Institute (MNI), McGill University, demonstrates that statin therapy in ... nervous system. The findings, published in The American ...
... to model in mice because their symptoms are complex ... when transferred to a mouse. The lack of animal ... By strategically altering a protein-making molecule, a mouse was ... feeling and cause paralysis of the arms and legs ...
Cached Biology News:One size does not fit all 2A new mouse model provides insight into genetic neurological disorders 2
Alexa Fluor 647 anti-mouse Qa-2...
... 100 IS System is ideal for developing ... reagents. This system contains the new, improved, ... Luminex. The user can design specific templates ... system has fully integrated graphing and data ...
Mouse monoclonal [0.T.81] to Lac1 ( Abpromise for all tested applications). Antigen: Recombinant TrpE fusion protein containing full length E. coli Lac1....
... Sweep- based acquision and analysis ... response type applications. Contains powerful ... flexible analysis functions including automated ... plotting. Also includes many electrophysiology ...
Biology Products: